Revance Therapeutics, Inc.

RVNC · NASDAQ
Analyze with AI
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Activities
Net Income-$324-$356-$281-$282
Dep. & Amort.$14$39$20$10
Deferred Tax$0$0$0-$3
Stock-Based Comp.$48$52$43$36
Change in WC-$44$1-$5$40
Other Non-Cash$90$71$1$20
Operating Cash Flow-$217-$194-$222-$179
Investing Activities
PP&E Inv.-$7-$23-$18-$4
Net Acquisitions$0$20$8-$1
Inv. Purchases-$264-$348-$184-$259
Inv. Sales/Matur.$385$232$172$276
Other Inv. Act.-$5-$20-$8$17
Investing Cash Flow$110-$139-$30$12
Financing Activities
Debt Repay.$30$87$0$288
Stock Issued$100$248$22$84
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$6-$3$8-$40
Financing Cash Flow$137$332$30$331
Forex Effect$0$0$0$0
Net Chg. in Cash$30-$1-$221$165
Supplemental Information
Beg. Cash$115$116$337$172
End Cash$145$115$116$337
Free Cash Flow-$223-$217-$240-$183